

PRESS RELEASE

Cordlife Wins 2015 Frost & Sullivan Singapore Stem Cell Banking Company of the Year Award

Singapore, 16 October 2015 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a mother and child consumer healthcare company, announced today that it was chosen as the award recipient for the 2015 Frost & Sullivan Singapore Stem Cell Banking Company of the Year.

The Frost & Sullivan Best Practices team of industry experts has been presenting awards to companies demonstrating best practices in a variety of regional and global markets. As Frost & Sullivan’s Best Practices Recognition program focuses upon bringing positive change by inspiring companies, customers and investors to accelerate the degree of change towards new technology, business models and leadership techniques to address the global challenges. Specifically, the Singapore Stem Cell Banking Company of the Year awarded by Frost & Sullivan recognises companies which made contributions in supporting the stem cell industry in Singapore.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said: “We are pleased to be chosen as the winner of the 2015 Frost & Sullivan Singapore Stem Cell Banking Company of the Year Award following thorough market analysis and in-depth interviews by Frost & Sullivan, a global consulting firm that provides market research and analysis across multiple industries. This award serves as a validation of the Company’s ongoing contributions in developing the stem cell banking industry in Singapore. As a trusted provider of consumer healthcare products and services catering to mothers and their children since our founding in 2001, we are deeply honoured that thousands of parents have trusted us to store and safeguard their babies’ precious cord blood and cord lining. Looking ahead, we are hopeful that the scope of application of cord blood and cord lining stem cells in the treatment of various medical conditions will widen and we want to continue playing a part in the betterment of the well-being and health of both mother and child.”

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has the largest market share of private cord blood banks in Singapore, Indonesia and the Philippines¹. In Hong Kong and India, it is amongst the top three market leaders for private cord blood banks.

Cordlife, through its collaborative relationships and arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking service in Singapore. In October 2013, Cordlife also acquired a 19.92% stake, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad (“StemLife”). StemLife is a fully licensed cord blood banking facility with the Ministry of Health Malaysia currently listed on the ACE Market of Bursa Malaysia.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy. In addition, in April 2013, Cordlife became the first private cord blood bank in Asia to have launched SEPAX^{®2}, a Swiss-made FDA-approved, GMP compliant automated stem cell processing system that maximises automation while ensuring consistently high cell recoveries.

Cordlife’s track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards Year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; 2014 Most Popular Stem Cell Bank Reader’s Choice by Child Magazine; 2013-2014 MyBB Parent-Child Favorite Cord Blood and Umbilical Cord Bank Company and Baby Kingdom Top 10 Family Brand Award 2012². In October 2012, Cordlife was awarded the prestigious SIAS Investors’ Choice Awards as runner-up in the “Most Transparent Company Award 2012” New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, “Best Investor Relations Award”. In November 2013, Cordlife was named the “Most Transparent Company 2013” in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors’ Choice Awards.

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, October 2014

² Awarded to Cordlife (Hong Kong) Limited

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Kamal Samuel / Mr Mark Lin
OFFICE : 6438-2990
EMAIL : kamal@financialpr.com.sg / marklin@financialpr.com.sg
